Latest From Pfenex Inc.
Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.
The EMA has formally accepted for filing Alvogen and Pfenex’ centralized marketing authorization application for a biosimilar rival to Lilly’s Forsteo teriparatide blockbuster.
Alvogen is conducting a study directing comparing its teriparatide delivery device with that of Lilly’s Forteo in a bid to be substitutable in the US for Pfizer’s original. The firm’s partner, Alvogen, has just filed the osteoporosis drug under Europe’s centralized procedure.
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Generic Drugs
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfenex Inc.
- Senior Management
Evert (Eef) Schimmelpennink, Pres. & CEO
Susan Knudson, CFO
Patrick K Lucy, CBO
Hubert C Chen, MD, CMO & CSO
- Contact Info
Phone: (858) 352-4400
10790 Roselle St.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.